1.
|
R MalekzadehF BishehsariM MahdaviniaR
AnsariEpidemiology and molecular genetics of colorectal cancer in
Iran: a reviewArch Iran Med12161169200919249887
|
2.
|
A SadjadiM NouraieMA MohagheghiA
Mousavi-JarrahiR MalekzadehDM ParkinCancer occurrence in Iran in
2002: an international perspectiveAsian Pac J Cancer
Prev6359363200516236000
|
3.
|
V CatalanoAM BaldelliP GiordaniS
CascinuMolecular markers predictive of response to chemotherapy in
gastrointestinal tumorsCrit Rev Oncol
Hematol3893104200110.1016/S1040-8428(00)00114-111311657
|
4.
|
WT BeckCircumvention of multidrug
resistance with anti-P-glycoprotein antibodies: clinical potential
or experimental artifact?J Natl Cancer
Inst877375199510.1093/jnci/87.2.73
|
5.
|
M TakanoR YumotoT MurakamiExpression and
function of efflux drug transporters in the intestinePharmacol
Ther109137161200610.1016/j.pharmthera.2005.06.00516209890
|
6.
|
GE SanduskyKS MintzeSE PrattAH
DantzigExpression of multidrug resistance-associated protein 2
(MRP2) in normal human tissues and carcinomas using tissue
microarraysHistopathology416574200210.1046/j.1365-2559.2002.01403.x
|
7.
|
R KerbS HoffmeyerU BrinkmannABC drug
transporters: hereditary polymorphisms and pharmacological impact
in MDR1, MRP1 and
MRP2Pharmacogenomics25164200110.1517/14622416.2.1.5111258197
|
8.
|
R OhashiF TakahashiR CuiInteraction
between CD44 and hyaluronate induces chemoresistance in non-small
cell lung cancer cellCancer
Lett252225234200710.1016/j.canlet.2006.12.02517276588
|
9.
|
K TaniguchiM WadaK KohnoA human
canalicular multispecific organic anion transporter (cMOAT) gene is
overexpressed in cisplatin-resistant human cancer cell lines with
decreased drug accumulationCancer Res56412441291996
|
10.
|
E BakosR EversE SinkóA VáradiP BorstB
SarkadiInteractions of the human multidrug resistance proteins MRP1
and MRP2 with organic anionsMol Pharmacol57760768200010727523
|
11.
|
E CasadoJ De CastroC
Belda-IniestaMolecular markers in colorectal cancer: genetic bases
for a customised treatmentClin Transl
Oncol9549554200710.1007/s12094-007-0102-817921101
|
12.
|
S GiacchettiB PerpointR ZidaniPhase III
multicenter randomized trial of oxaliplatin added to
chronomodulated fluorouracil-leucovorin as first-line treatment of
metastatic colorectal cancerJ Clin Oncol181361472000
|
13.
|
WL AllenVM CoylePG JohnstonPredicting the
outcome of chemotherapy for colorectal cancerCurr Opin
Pharmacol6332336200610.1016/j.coph.2006.02.00516750422
|
14.
|
CA RabikME DolanMolecular mechanisms of
resistance and toxicity associated with platinating agentsCancer
Treat Rev33923200710.1016/j.ctrv.2006.09.00617084534
|
15.
|
K ZhangP MackKP WongGlutathione-related
mechanisms in cellular resistance to anticancer drugsInt J
Oncol1287188219989499449
|
16.
|
Y ItohM TamaiK YokogawaInvolvement of
multidrug resistance-associated protein 2 in in vivo cisplatin
resistance of rat hepatoma AH66 cellsAnticancer
Res2216491653200212168849
|
17.
|
B LiedertV MaternaD SchadendorfJ ThomaleH
LageOverexpression of cMOAT (MRP2/ABCC2) is associated with
decreased formation of platinum-DNA adducts and decreased G2-arrest
in melanoma cells resistant to cisplatinJ Invest
Dermatol121172176200310.1046/j.1523-1747.2003.12313.x12839578
|
18.
|
K ShenD CuiL SunM HanJ LiuInhibition of
IGF-IR increases chemosensitivity in human colorectal cancer cells
through MRP-2 promoter suppressionJ Cell BiochemJan242012(Epub
ahead of print)
|
19.
|
LH SobinC WittekindInternational Union
Against CancerTNM Classification of Malignant Tumors6th editionJohn
Wiley & SonsNew Jersey2002
|
20.
|
HJ ArtsD KatsarosEG de VriesDrug
resistance associated markers P-glycoprotein, multidrug resistance
associated protein 1, multidrug resistance-associated protein 2,
and lung resistance protein as prognostic factors in ovarian
carcinomaClin Cancer Res5279828051999
|
21.
|
R UshijimaK TakayamaUM
IzumiImmunohistochemical expression of MRP2 and clinical resistance
to platinum-based chemotherapy in small cell lung cancerAnticancer
Res2743514358200718214043
|
22.
|
T AndréC BoniL
Mounedji-BoudiafOxaliplatin, fluorouracil, and leucovorin as
adjuvant treatment for colon cancerN Engl J Med350234323512004
|
23.
|
E HinoshitaT UchiumiK TaguchiIncreased
expression of an ATP-binding cassette superfamily transporter,
multidrug resistance protein 2, in human colorectal carcinomasClin
Cancer Res6240124072000
|
24.
|
P BorstR EversM KoolJ WijnholdsA family of
drug transporters: the multidrug resistance-associated proteinsJ
Natl Cancer Inst9212951302200010.1093/jnci/92.16.129510944550
|
25.
|
M YamasakiT MakinoT MasuzawaRole of
multidrug resistance protein 2 (MRP2) in chemoresistance and
clinical outcome in oesophageal squamous cell carcinomaBr J
Cancer104707713201110.1038/sj.bjc.660607121206495
|
26.
|
GB Van den BroekM WildemanCR
RaschMolecular markers predict outcome in squamous cell carcinoma
of the head and neck after concomitant cisplatin-based
chemoradiationInt J Cancer12426432650200919253368
|
27.
|
A MaciejczykE JagodaT WysockaR MatkowskiB
GyörffyH LageP SurowiakABCC2 (MRP2, cMOAT) localized in the nuclear
envelope of breast carcinoma cells correlates with poor clinical
outcomePathol Oncol
Res18331342201210.1007/s12253-011-9449-921986666
|